Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Usefulness of pregnancy-associated plasma protein A in patients with acute coronary syndrome

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A Validated Echocardiographic Risk Model for Predicting Outcome Following ST-segment Elevation Myocardial Infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial)

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Low-Dose Radiation to COVID-19 Patients to Ease the Disease Course and Reduce the Need of Intensive Care

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk for infective endocarditis in bacteremia with Gram positive cocci

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Response to letter of concern regarding »Reduction in COVID-19 infection using surgical facial masks outside the healthcare system«

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
To investigate whether pregnancy-associated plasma protein-A (PAPP-A) is a prognostic marker in patients admitted with high-risk acute coronary syndrome. In patients admitted with high-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and ST-segment elevation myocardial infarction (STEMI), risk stratification is primarily determined by the markers of myocardial necrosis and known demographic risk profiles. However, it has recently been proposed that the presence and extent of vulnerable plaques might influence the prognosis significantly. A marker for the vulnerable plaque could identify patients at high risk who would potentially benefit from intensive treatment and surveillance. Two populations of consecutive patients admitted with high-risk NSTE-ACS (n = 123) and STEMI (n = 314) were evaluated with serial measurements of PAPP-A. The incidence of mortality and nonfatal myocardial infarction was prospectively registered for 2.66 to 3.47 years. In the patients with high-risk NSTE-ACS, PAPP-A was related to the risk of nonfatal myocardial infarction (p = 0.02) and death (p = 0.03). This result was consistent on multivariate analysis of the combination of mortality or nonfatal myocardial infarction (odds ratio 2.65, 95% confidence interval 1.40 to 5.03) but not for mortality alone (p = NS). In patients with STEMI, PAPP-A was related to the risk of death (p = 0.01) but not the composite outcome of myocardial infarction and death. This was also true after adjustment for other univariate predictors of death (odds ratio 2.19, 95% confidence interval 1.16 to 4.16). In conclusion, PAPP-A seems to be valuable in predicting the outcomes of patients admitted with high-risk NSTE-ACS or STEMI.
Original languageEnglish
JournalThe American journal of cardiology
Volume104
Issue number11
Pages (from-to)1465-71
Number of pages6
DOIs
Publication statusPublished - 2009

Bibliographical note

Keywords: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Biological Markers; Denmark; Electrocardiography; Female; Hospitals, District; Hospitals, University; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Pregnancy; Pregnancy-Associated Plasma Protein-A; Prognosis; Prospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate

ID: 171149